ART's SoftScan demonstrates 88% specificity in breast tissue

By Lisa Kerner

Charlotte, N.C., Sept. 13 - ART Advanced Research Technologies Inc. said results from a multi-site clinical study of its SoftScan optical imaging device showed significant discrimination between malignant and healthy tissue based on the oxy-hemoglobin index in the breast, with sensitivity and specificity rates of 88%.

Among the 105 persons between ages 31 and 74 scanned, 29 were healthy volunteers with negative mammograms and 76 women were patients with abnormal findings scheduled for tissue biopsy or surgical excision.

Following mammograms and biopsies, the study was left with an evaluable sample of 15 patients with a variety of malignant lesions, 25 with a benign disease and 29 with normal tissue.

ART is a medical device company based in Montreal.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.